PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Targeted therapy - Market size and forecast 2018-2023 • Chemotherapy - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Increasing R&D of new drugs • Development of nanotechnology-based drug delivery systems • Patient assistance programs PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca Plc • Bristol-Myers Squibb Co. • Eli Lilly and Co. • Endo International Plc • F. Hoffmann-La Roche Ltd. • Merck & Co., Inc. • Mylan NV • Pfizer Inc. • Sanofi • Teva Pharmaceutical Industries Ltd. PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Vendors: Key offerings Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Targeted therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Combination therapies under development Exhibit 22: Targeted therapy - Year-over-year growth 2019-2023 (%) Exhibit 23: Chemotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Chemotherapy - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by product Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Top 3 countries in North America Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in Europe Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Asia Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in ROW Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Impact of drivers and challenges Exhibit 44: Vendor landscape Exhibit 45: Landscape disruption Exhibit 46: Vendors covered Exhibit 47: Vendor classification Exhibit 48: Market positioning of vendors Exhibit 49: AstraZeneca Plc - Vendor overview Exhibit 50: AstraZeneca Plc - Business segments Exhibit 51: AstraZeneca Plc - Organizational developments Exhibit 52: AstraZeneca Plc - Geographic focus Exhibit 53: AstraZeneca Plc - Key offerings Exhibit 54: AstraZeneca Plc - Key customers Exhibit 55: Bristol-Myers Squibb Co. - Vendor overview Exhibit 56: Bristol-Myers Squibb Co. - Product segments Exhibit 57: Bristol-Myers Squibb Co. - Organizational developments Exhibit 58: Bristol-Myers Squibb Co. - Geographic focus Exhibit 59: Bristol-Myers Squibb Co. - Key offerings Exhibit 60: Bristol-Myers Squibb Co. - Key customers Exhibit 61: Eli Lilly and Co. - Vendor overview Exhibit 62: Eli Lilly and Co. - Business segments Exhibit 63: Eli Lilly and Co. - Organizational developments Exhibit 64: Eli Lilly and Co. - Geographic focus Exhibit 65: Eli Lilly and Co. - Segment focus Exhibit 66: Eli Lilly and Co. - Key offerings Exhibit 67: Eli Lilly and Co. - Key customers Exhibit 68: Endo International Plc - Vendor overview Exhibit 69: Endo International Plc - Business segments Exhibit 70: Endo International Plc - Organizational developments Exhibit 71: Endo International Plc - Geographic focus Exhibit 72: Endo International Plc - Segment focus Exhibit 73: Endo International Plc - Key offerings Exhibit 74: Endo International Plc - Key customers Exhibit 75: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 76: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 77: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 78: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 79: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 80: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 81: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 82: Merck & Co. Inc. - Vendor overview Exhibit 83: Merck & Co. Inc. - Business segments Exhibit 84: Merck & Co. Inc. - Organizational developments Exhibit 85: Merck & Co. Inc. - Geographic focus Exhibit 86: Merck & Co. Inc. - Segment focus Exhibit 87: Merck & Co. Inc. - Key offerings Exhibit 88: Merck & Co. Inc. - Key customers Exhibit 89: Mylan NV - Vendor overview Exhibit 90: Mylan NV - Product segments Exhibit 91: Mylan NV - Organizational developments Exhibit 92: Mylan NV - Geographic focus Exhibit 93: Mylan NV - Segment focus Exhibit 94: Mylan NV - Key offerings Exhibit 95: Mylan NV - Key customers Exhibit 96: Pfizer Inc. - Vendor overview Exhibit 97: Pfizer Inc. - Business segments Exhibit 98: Pfizer Inc. - Organizational developments Exhibit 99: Pfizer Inc. - Geographic focus Exhibit 100: Pfizer Inc. - Segment focus Exhibit 101: Pfizer Inc. - Key offerings Exhibit 102: Pfizer Inc. - Key customers Exhibit 103: Sanofi - Vendor overview Exhibit 104: Sanofi - Business segments Exhibit 105: Sanofi - Organizational developments Exhibit 106: Sanofi - Geographic focus Exhibit 107: Sanofi - Segment focus Exhibit 108: Sanofi - Key offerings Exhibit 109: Sanofi - Key customers Exhibit 110: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 111: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 112: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 113: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 116: Validation techniques employed for market sizing Exhibit 117: Definition of market positioning of vendors

AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., Endo International Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.